| All Releases |
|---|
 |
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
Sep 29, 2008
|
10.2 KB
|
| |
SAN DIEGO, Sept 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroed...
|
|
|
Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
Sep 15, 2008
|
12.9 KB
|
| |
SAN DIEGO, Sept 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that it has revised the expected timing of its announcement of results for the CLIRS trial, the company's Phase III clinical trial of Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of c...
|
|
|
Cadence Pharmaceuticals Appoints Todd Rich, M.D. to its Board of Directors and Names Malcolm Lloyd-Smith as Senior Vice President, Regulatory Affairs and Quality Assurance
Aug 28, 2008
|
13.9 KB
|
| |
SAN DIEGO, Aug 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today the appointments of Todd Rich, M.D. to the company's board of directors and Malcolm Lloyd-Smith to the position of Senior Vice President, Regulatory Affairs and Quality Assurance. Mr. Lloyd-Smith assumes the role pr...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
Aug 27, 2008
|
10.2 KB
|
| |
SAN DIEGO, Aug 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroede...
|
|
|
Cadence Pharmaceuticals Reports Second Quarter 2008 Financial Results and Provides Overview of Clinical Programs
Aug 7, 2008
|
18.0 KB
|
| |
SAN DIEGO, Calif., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the for the second quarte...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
Aug 4, 2008
|
10.4 KB
|
| |
SAN DIEGO, Aug 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroede...
|
|
|
Cadence Pharmaceuticals Announces FDA Concurrence With Clinical Development Plan for Acetavance(TM)
Jul 30, 2008
|
14.2 KB
|
| |
SAN DIEGO, July 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that it has received written guidance from the U.S. Food and Drug Administration (FDA) that one post-operative pain trial (Sinatra Study) and one fever trial (Study 302) are sufficient to meet the pivotal clinical ...
|
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
Jul 28, 2008
|
10.5 KB
|
| |
SAN DIEGO, July 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its second quarter financial res...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
Jun 17, 2008
|
10.2 KB
|
| |
SAN DIEGO, June 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroed...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
Jun 4, 2008
|
10.3 KB
|
| |
SAN DIEGO, June 4, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroede...
|
|
|
Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
May 6, 2008
|
20.7 KB
|
| |
SAN DIEGO, May 6, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the quarter ended March 31, 2008 a...
|
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
Apr 30, 2008
|
10.5 KB
|
| |
SAN DIEGO, April 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its first quarter financial res...
|
|
|
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
Apr 30, 2008
|
10.6 KB
|
| |
SAN DIEGO, April 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroe...
|
|
|
Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
Mar 13, 2008
|
10.3 KB
|
| |
SAN DIEGO, March 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Senior Vice President and CFO William R. LaRue ...
|
|
|
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
Mar 12, 2008
|
20.9 KB
|
| |
SAN DIEGO, March 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the quarter and year ended Dece...
|
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
Mar 6, 2008
|
10.5 KB
|
| |
SAN DIEGO, March 6, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year...
|
|
|
Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
Feb 20, 2008
|
12.1 KB
|
| |
SAN DIEGO, Feb 20, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it completed its previously announced registered ...
|
|
|
Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Feb 15, 2008
|
10.0 KB
|
| |
SAN DIEGO, Feb 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Cadence has received commitments from selected inv...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
Jan 31, 2008
|
10.2 KB
|
| |
SAN DIEGO, Jan 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroede...
|
|
|
Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
Jan 11, 2008
|
17.4 KB
|
| |
SAN DIEGO, Jan 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced top line results of two of the company's four pivotal, Phase III clinical trials of Acetavance(TM), a formulation of acetaminophen for intravenous use. One of these clinical trials did not meet its primary endpoint ...
|
|
|
